Brief: Timber Pharmaceuticals' Development Partner, Aft Pharmaceuticals, Enter Licensing Agreement For Pascomer In Europe
March 17 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS’ DEVELOPMENT PARTNER, AFT
PHARMACEUTICALS, ENTERS INTO LICENSING AGREEMENT FOR PASCOMER®
(TMB-002) IN EUROPE
* TIMBER - EXTENSION OF AGREEMENT WITH AFT PHARMACEUTICALS
GRANTS
DESITIN ARZNEIMITTEL GMBH EXCLUSIVE LICENSE, SUPPLY RIGHTS FOR
TMB-002 IN EUROPE
Source text for Eikon: ID:nGNX2kWFWp
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing